
    
      For approximately 72 patients enrolled in the dose-finding and second portions, the total
      study duration per patient will be 166 weeks that will consist of a 4- week screening, a
      12-week core treatment phase, a 144-week extension phase, and a 6-week post-treatment
      follow-up. For approximately 28 patients enrolled in the third portion, the total study
      duration per patient will be 106 weeks that will consist of a 4- week screening, a 12-week
      core treatment phase, a 84-week extension phase, and a 6-week post-treatment follow-up.
    
  